Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...

Retatrutide, Eli Lilly’s triple-hormone obesity drug, delivers up to 28.7% weight loss and major knee pain relief in ...

Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...

Investing.com -- Moody’s Ratings has affirmed Eli Lilly and Company ’s Aa3 senior unsecured notes ratings and long-term issuer rating while revising the outlook to positive from stable, the rating ...

USA: A first-in-class triple hormone receptor agonist, retatrutide, has demonstrated striking reductions in body weight along ...

But even as Ozempic enters India, there is a growing sense globally that Novo may have already lost the obesity drug war to Mounjaro, Eli Lilly’s blockbuster that has become India’s top-selling drug ...

Eggoz Cancer Controversy Explained: Should You Really Worry and What Type of Eggs You Should Eat Now - ...

The athletic apparel company said Chief Executive Officer Calvin McDonald will step down in January and relinquish his board ...

The clinical trial showed this experimental medication to be much more effective than any existing GLP-1 drug. But that much ...

News Quiz for Dec. 13, 2025 ...